Roche and England’s NICE are again in an arm-wrestling contest, this time over the use of Roche’s cancer drug Tecentriq for metastatic urothelial cancer.…
Patients with a specific type of acute myeloid leukemia have their first treatment option with an FDA approval Tuesday.
Bristol-Myers Squibb and Clovis Oncology plan to pair two of their oncology drugs in several cancer types.
Eli Lilly’s RA med baricitinib had been pegged as one of 2017’s hottest launches—and a threat to Pfizer’s Xeljanz. Not anymore.
Thousands of FDA employees will get a reprieve instead of pink slips next week as FDA Commissioner Scott Gottlieb gave them encouraging job news.
The immunotherapy mystery deepens. Merck’s Keytruda missed its goal in a head and neck cancer trial—one its Bristol-Myers rival Opdivo met last year.
The FDA, insurers and PBMs are set to explore ways to fight the opioid epidemic.
Democrats rolled out their new economic agenda Monday, calling it a “Better Deal.” For consumers, maybe. For the pharma industry, not so much.
GlaxoSmithKline hopes to get its new Benlysta formula under lupus patients’ skin—literally.
Analysts expect Nerlynx to gin up blockbuster sales by 2022, thanks to a 'best case' approval from the FDA.